Analysis of the genome to personalize therapy for melanoma

M. A. Davies; Y. Samuels

doi:10.1038/onc.2010.323

Analysis of the genome to personalize therapy for melanoma

M. A. Davies, Y. Samuels

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

109 Scopus citations

Abstract

The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.

Original language	English (US)
Pages (from-to)	5545-5555
Number of pages	11
Journal	Oncogene
Volume	29
Issue number	41
DOIs	https://doi.org/10.1038/onc.2010.323
State	Published - Oct 14 2010

Keywords

BRAF
C-KIT
ERBB4
GNαQ
NRAS
melanoma

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/onc.2010.323

Cite this

@article{e3038e370e1c476583481f85873f5f6e,

title = "Analysis of the genome to personalize therapy for melanoma",

abstract = "The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.",

keywords = "BRAF, C-KIT, ERBB4, GNαQ, NRAS, melanoma",

author = "Davies, {M. A.} and Y. Samuels",

note = "Funding Information: We thank Darryl Leja for graphical expertize and Nature Genetics for permission to use figures from paper doi:10.1038/ ng.438. This work was supported by grants from ASCO (Young Investigator Award) and M D Anderson Cancer Center SPORE in Melanoma (Developmental Research Grant; 5 P50 CA093459 03 PP-DRP3; to MAD) and the Intramural Research Programs of the National Human Genome Research Institute, National Institutes of Health, USA (to YS).",

year = "2010",

month = oct,

day = "14",

doi = "10.1038/onc.2010.323",

language = "English (US)",

volume = "29",

pages = "5545--5555",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "41",

}

TY - JOUR

T1 - Analysis of the genome to personalize therapy for melanoma

AU - Davies, M. A.

AU - Samuels, Y.

N1 - Funding Information: We thank Darryl Leja for graphical expertize and Nature Genetics for permission to use figures from paper doi:10.1038/ ng.438. This work was supported by grants from ASCO (Young Investigator Award) and M D Anderson Cancer Center SPORE in Melanoma (Developmental Research Grant; 5 P50 CA093459 03 PP-DRP3; to MAD) and the Intramural Research Programs of the National Human Genome Research Institute, National Institutes of Health, USA (to YS).

PY - 2010/10/14

Y1 - 2010/10/14

N2 - The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.

AB - The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.

KW - BRAF

KW - C-KIT

KW - ERBB4

KW - GNαQ

KW - NRAS

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=77957982878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957982878&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.323

DO - 10.1038/onc.2010.323

M3 - Review article

C2 - 20697348

AN - SCOPUS:77957982878

SN - 0950-9232

VL - 29

SP - 5545

EP - 5555

JO - Oncogene

JF - Oncogene

IS - 41

ER -

Analysis of the genome to personalize therapy for melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this